246 related articles for article (PubMed ID: 35758129)
1. [Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].
Di Guardo L
Recenti Prog Med; 2022 Jun; 113(6):28e-30e. PubMed ID: 35758129
[TBL] [Abstract][Full Text] [Related]
2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
4. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
Trojaniello C; Festino L; Vanella V; Ascierto PA
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
[TBL] [Abstract][Full Text] [Related]
5. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
[TBL] [Abstract][Full Text] [Related]
6. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
Corrie P; Meyer N; Berardi R; Guidoboni M; Schlueter M; Kolovos S; Macabeo B; Trouiller JB; Laramée P
Cancer Treat Rev; 2022 Nov; 110():102463. PubMed ID: 36099854
[TBL] [Abstract][Full Text] [Related]
8. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D; Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Yamazaki N; Queirolo P; Guenzel C; Polli A; Thakur M; di Pietro A; Ascierto PA
Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373
[TBL] [Abstract][Full Text] [Related]
9. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
Rose AAN
Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients.
Indini A; Mandalà M
Expert Opin Drug Saf; 2020 Oct; 19(10):1229-1236. PubMed ID: 32857940
[TBL] [Abstract][Full Text] [Related]
11. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
Gogas H; Dummer R; Ascierto PA; Arance A; Mandalà M; Liszkay G; Garbe C; Schadendorf D; Krajsová I; Gutzmer R; Sileni VC; Dutriaux C; Yamazaki N; Loquai C; Queirolo P; Jan de Willem G; Sellier AT; Suissa J; Murris J; Gollerkeri A; Robert C; Flaherty KT
Eur J Cancer; 2021 Jul; 152():116-128. PubMed ID: 34091420
[TBL] [Abstract][Full Text] [Related]
13. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable
Schadendorf D; Dummer R; Robert C; Ribas A; Sullivan RJ; Panella T; McKean M; Santos ES; Brill K; Polli A; Pietro AD; Ascierto PA
Future Oncol; 2022 Jun; 18(17):2041-2051. PubMed ID: 35272485
[TBL] [Abstract][Full Text] [Related]
14. Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.
Fujimura T; Yoshino K; Kato H; Fujisawa Y; Nakamura Y; Yamamoto Y; Kunimoto K; Ito T; Matsushita S; Maekawa T; Ohuchi K; Amagai R; Muto Y; Furudate S; Kambayashi Y; Hashimoto A; Aiba S
J Dermatol; 2021 Mar; 48(3):397-400. PubMed ID: 33179310
[TBL] [Abstract][Full Text] [Related]
15. [Treatment combinations in BRAF-mutant metastatic melanoma.].
Depenni R
Recenti Prog Med; 2021 Apr; 112(4):40e-43e. PubMed ID: 33877098
[TBL] [Abstract][Full Text] [Related]
16. [Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.].
Cerro M; Maccallini MT; Russillo M
Recenti Prog Med; 2024 May; 115(5):13e-16e. PubMed ID: 38708541
[TBL] [Abstract][Full Text] [Related]
17. The discovery and development of binimetinib for the treatment of melanoma.
Tran B; Cohen MS
Expert Opin Drug Discov; 2020 Jul; 15(7):745-754. PubMed ID: 32249628
[TBL] [Abstract][Full Text] [Related]
18. Switch from dabrafenib/trametinib combination therapy to encorafenib/binimetinib combination therapy with transition of serum lactate dehydrogenase level in melanoma: A case report.
Sato T; Noto M; Yamada M; Kono M
Dermatol Ther; 2022 Apr; 35(4):e15301. PubMed ID: 34984776
[No Abstract] [Full Text] [Related]
19. Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
Ngo P; Bycroft R
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527213
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.
Trouiller JB; Nikolaidis GF; Macabeo B; Meyer N; Gerlier L; Schlueter M; Laramee P
Eur J Health Econ; 2024 Jun; 25(4):641-653. PubMed ID: 37433888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
